GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Dexamethasone Tablets USP, 1 mg had annual sales of US$ 1.8 mn in the United States (IQVIA MAT March 24)
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Around 7% of the Indian population suffers from IBS
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Subscribe To Our Newsletter & Stay Updated
